A recent evaluation of melanoma patients receiving combination anti-CTLA-4 and anti-PD-1 found that increased IL-17a/IL-17f signaling was positively associated with immune infiltration and improved clinical outcomes; however, this relationship did not extend to patients treated with monotherapy (82). Here, PDCD1 is linked to melanoma.